A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Byers, Lauren; Navarro, Alejandro; Schaefer, Eric; Johnson, Melissa; Ozguroglu, Mustafa; Han, Ji-Youn; Bondarenko, Igor; ÇİÇİN, İRFAN; Dragnev, Konstantin; Abel, Adam; Wang, Xuejing; McNeely, Samuel; Hynes, Scott; Lin, Aimee; Forster, Martin

doi:10.1016/j.cllc.2021.04.005

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Byers L. A., Navarro A., Schaefer E., Johnson M., Ozguroglu M., Han J., ...Daha Fazla

CLINICAL LUNG CANCER, cilt.22, sa.6, ss.531-540, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 6
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.cllc.2021.04.005
Dergi Adı: CLINICAL LUNG CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.531-540
Anahtar Kelimeler: Checkpoint kinase 1 inhibitor, Relapsed, Refractory, Small cell lung cancer, Pharmacokinetics, Biomarker, 2ND-LINE TREATMENT, TOPOTECAN, CYCLOPHOSPHAMIDE, VINCRISTINE, CISPLATIN
İstanbul Üniversitesi Adresli: Evet

Özet

Patients with extensive-stage small-cell lung cancer (ED-SCLC) need improved outcomes in the relapsed/refractory setting. This phase II study evaluated the safety and efficacy of prexasertib, a checkpoint kinase 1 inhibitor, in platinum-sensitive and platinum-refractory ED-SCLC. Prexasertib demonstrated response rates of 5.2% in platinum-sensitive and 0% in platinum-refractory ED-SCLC. Prexasertib did not show prespecified efficacy as monotherapy in ED-SCLC.